Page last updated: 2024-10-19
niacin and Orthopedic Disorders
niacin has been researched along with Orthopedic Disorders in 1 studies
Niacin: A water-soluble vitamin of the B complex occurring in various animal and plant tissues. It is required by the body for the formation of coenzymes NAD and NADP. It has PELLAGRA-curative, vasodilating, and antilipemic properties.
vitamin B3 : Any member of a group of vitamers that belong to the chemical structural class called pyridines that exhibit biological activity against vitamin B3 deficiency. Vitamin B3 deficiency causes a condition known as pellagra whose symptoms include depression, dermatitis and diarrhea. The vitamers include nicotinic acid and nicotinamide (and their ionized and salt forms).
nicotinic acid : A pyridinemonocarboxylic acid that is pyridine in which the hydrogen at position 3 is replaced by a carboxy group.
Research Excerpts
| Excerpt | Relevance | Reference |
|---|
| "Niacin-laropiprant was associated with an increased incidence of disturbances in diabetes control that were considered to be serious (absolute excess as compared with placebo, 3." | 2.79 | Effects of extended-release niacin with laropiprant in high-risk patients. ( Armitage, J; Aung, T; Collins, R; Craig, M; Haynes, R; Hopewell, JC; Jiang, L; Landray, MJ; Parish, S; Tomson, J; Wallendszus, K, 2014) |
Research
Studies (1)
| Timeframe | Studies, this research(%) | All Research% |
|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
Authors
| Authors | Studies |
|---|
| Landray, MJ | 1 |
| Haynes, R | 1 |
| Hopewell, JC | 1 |
| Parish, S | 1 |
| Aung, T | 1 |
| Tomson, J | 1 |
| Wallendszus, K | 1 |
| Craig, M | 1 |
| Jiang, L | 1 |
| Collins, R | 1 |
| Armitage, J | 1 |
Clinical Trials (1)
Trial Overview
| Trial | Phase | Enrollment | Study Type | Start Date | Status |
|---|
| A Randomized Trial of the Long-term Clinical Effects of Raising HDL Cholesterol With Extended Release Niacin/Laropiprant[NCT00461630] | Phase 3 | 25,673 participants (Actual) | Interventional | 2007-01-31 | Completed |
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] |
Trial Outcomes
Coronary or Non-coronary Revascularisation
(NCT00461630)
Timeframe: During scheduled treatment period (median duration 3.9 years)
| Intervention | participants (Number) |
|---|
| ER Niacin/Laropiprant | 807 |
| Placebo | 897 |
Major Coronary Events
Non-fatal myocardial infarction (MI) or coronary death (NCT00461630)
Timeframe: During scheduled treatment period (median duration 3.9 years)
| Intervention | participants (Number) |
|---|
| ER Niacin/Laropiprant | 668 |
| Placebo | 694 |
Major Vascular Event
Non-fatal myocardial infarction or coronary death, non-fatal or fatal stroke, or revascularisation (NCT00461630)
Timeframe: During scheduled treatment period (median duration 3.9 years)
| Intervention | participants (Number) |
|---|
| ER Niacin/Laropiprant | 1696 |
| Placebo | 1758 |
Mortality
All-cause mortality (NCT00461630)
Timeframe: During scheduled treatment period (median duration 3.9 years)
| Intervention | participants (Number) |
|---|
| ER Niacin/Laropiprant | 798 |
| Placebo | 732 |
Stroke
Fatal or non-fatal (NCT00461630)
Timeframe: During scheduled treatment period (median duration 3.9 years)
| Intervention | participants (Number) |
|---|
| ER Niacin/Laropiprant | 498 |
| Placebo | 499 |
Trials
1 trial available for niacin and Orthopedic Disorders